Background

Bone erosion in rheumatoid arthritis (RA) is conventionally attributed to TNF-α and IL-6-driven osteoclastogenesis. However, a subset of RA patients on effective anti-TNF therapy still exhibit progressive erosions despite suppressed inflammatory markers. Separately, senescent cells accumulate in the rheumatoid synovium and produce the senescence-associated secretory phenotype (SASP).

Hypothesis

Senescent synovial fibroblasts and macrophages in the RA pannus produce a SASP enriched in MMP-3, IL-8, and CCL2 that directly upregulates RANKL expression on osteoblast-lineage cells through a p38-MAPK/NF-κB axis that is independent of TNF-α signaling. This creates a TNF-refractory erosive pathway where senescent cell clearance, rather than further cytokine blockade, would halt bone destruction.

Testable Predictions

1. In vitro: Co-culture of senescence-induced (etoposide or irradiation) synovial fibroblasts with osteoblasts will increase RANKL/OPG ratio ≥2-fold compared to non-senescent controls, and this effect will persist in the presence of saturating anti-TNF antibody.
2. Ex vivo: RA synovial tissue sections from anti-TNF non-responders (erosion progressors) will show higher p16^INK4a+ cell density in subchondral bone-adjacent zones compared to erosion non-progressors, quantifiable by immunohistochemistry.
3. In vivo: Administration of the senolytic combination dasatinib + quercetin (D+Q) in collagen-induced arthritis (CIA) mice will reduce micro-CT erosion scores by ≥30% even when administered after anti-TNF (etanercept) has plateaued in efficacy.
4. Biomarker: Serum p16^INK4a mRNA (from circulating senescent cells) will correlate with radiographic progression (Sharp/van der Heijde score change) in a longitudinal RA cohort independently of CRP and ESR.

Significance

If confirmed, this would establish senolytic therapy as an adjunct to biologics in erosive RA, and identify p16^INK4a as a predictive biomarker for TNF-refractory erosion — bridging geroscience and rheumatology in a clinically actionable way.